A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

• Status: Recruiting
• Trial end date: 2024-06-01

Summary

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.

• Phase: Phase 2

Details

• Lead Sponsor: University of Rochester
• Treatments: Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine